Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.10 is 427% above its 2-year average of -0.03, near the high end of its 2-year range (-0.23–0.10).
As of the fiscal period ended Tuesday, June 30, 2026. 307.90% above its 12-month average of 0.02.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.10.
DEBT TO EQUITY RATIO
0.10
DEBT TO EQUITY RATIO AVG TTM
0.02
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+307.90%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 554 covered companies
CURRENT VS SECTOR MEDIAN
-25.40%
vs the sector median at left
Heartflow, Inc. Common Stock
Market Cap
$4.35B
Debt to Equity Ratio
0.10
TTM Avg
0.02
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.38B
Debt to Equity Ratio
N/A
TTM Avg
3.41
3Y Avg
2.92
5Y Avg
3.07
Market Cap
$4.41B
Debt to Equity Ratio
2.87
TTM Avg
0.86
3Y Avg
0.57
5Y Avg
0.43
Market Cap
$4.27B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$4.59B
Debt to Equity Ratio
0.04
TTM Avg
0.04
3Y Avg
0.07
5Y Avg
0.05
Market Cap
$4.65B
Debt to Equity Ratio
0.14
TTM Avg
0.24
3Y Avg
0.29
5Y Avg
0.27
Market Cap
$4.00B
Debt to Equity Ratio
0.15
TTM Avg
0.10
3Y Avg
0.09
5Y Avg
0.07
Market Cap
$4.71B
Debt to Equity Ratio
0.27
TTM Avg
0.44
3Y Avg
1.89
5Y Avg
1.89
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Heartflow, Inc. Common Stock (HTFL) | $4.35B | 0.10 | 0.02 | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.38B | N/A | 3.41 | 2.92 | 3.07 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.41B | 2.87 | 0.86 | 0.57 | 0.43 |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.27B | 0.01 | 0.01 | 0.01 | 0.01 |
| LivaNova PLC (LIVN)vs › | $4.14B | 0.27 | 0.45 | 0.47 | 0.46 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.59B | 0.04 | 0.04 | 0.07 | 0.05 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.65B | 0.14 | 0.24 | 0.29 | 0.27 |
| AbCellera Biologics Inc. (ABCL)vs › | $4.00B | 0.15 | 0.10 | 0.09 | 0.07 |
| BillionToOne, Inc. (BLLN)vs › | $4.71B | 0.27 | 0.44 | 1.89 | 1.89 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.72B | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Equity
0.10
Current Ratio
5.08
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.10 |
| 2026-03-31 | 0.09 |
| 2025-12-31 | 0.07 |
| 2025-09-30 | 0.09 |
| 2025-06-30 | -0.23 |
| 2025-03-31 | -0.23 |
| 2024-12-31 | -0.19 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
